| scholarly article | Q13442814 |
| P50 | author | Aaron Tan | Q82736921 |
| P2093 | author name string | Nick Pavlakis | |
| David L Chan | |||
| Wasek Faisal | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Chemotherapy for advanced gastric cancer | Q24236634 | ||
| Clinical significance of MET in gastric cancer | Q26776190 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence | Q28071772 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program | Q30313895 | ||
| HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer | Q30837184 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model | Q40182123 | ||
| Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 | ||
| Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial | Q42693879 | ||
| Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer | Q43471758 | ||
| Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials | Q44261463 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric o | Q50962654 | ||
| Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer | Q53249720 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer | Q53604465 | ||
| Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial | Q53837214 | ||
| Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer | Q54341358 | ||
| Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. | Q55322223 | ||
| MET Signaling Pathway: A Rational Target for Cancer Therapy | Q82286267 | ||
| An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer | Q84077312 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | Q89029141 | ||
| Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | Q90568939 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | Q33416122 | ||
| Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer | Q33712400 | ||
| Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions | Q33770680 | ||
| Biologic and therapeutic role of HER2 in cancer | Q34267775 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 | ||
| Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer | Q34608222 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Recent advances in the HER2 targeted therapy of gastric cancer | Q34967104 | ||
| Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer | Q35113261 | ||
| Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies | Q35288940 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. | Q35927364 | ||
| Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). | Q35981433 | ||
| Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). | Q36108820 | ||
| Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma | Q36172082 | ||
| The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis | Q36286390 | ||
| Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis | Q36604482 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| MET Expression and Amplification in Patients with Localized Gastric Cancer | Q36949256 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer | Q37235534 | ||
| Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study | Q37242288 | ||
| Advanced gastric cancer--slow but steady progress | Q37696790 | ||
| Prognostic Value of Vascular Endothelial Growth Factor Expression in Resected Gastric Cancer | Q38045008 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Q38829062 | ||
| Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 | ||
| Targeting the PD-1 pathway: a new hope for gastrointestinal cancers | Q39038545 | ||
| Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. | Q39172509 | ||
| Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial | Q39668099 | ||
| Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 | ||
| EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number | Q40105232 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gastroenterology | Q120569 |
| P304 | page(s) | 1756284818808072 | |
| P577 | publication date | 2018-11-14 | |
| P1433 | published in | Therapeutic Advances in Gastroenterology | Q21042423 |
| P1476 | title | New drug developments in metastatic gastric cancer | |
| P478 | volume | 11 |
| Q64966516 | A panel of collagen genes are associated with prognosis of patients with gastric cancer and regulated by microRNA-29c-3p: an integrated bioinformatics analysis and experimental validation. |
| Q64070248 | MIR100HG: a credible prognostic biomarker and an oncogenic lncRNA in gastric cancer |
| Q91718898 | The Aberrant Expression of MicroRNA-125a-5p/IGF2BP3 Axis in Advanced Gastric Cancer and Its Clinical Relevance |
Search more.